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Abstract 
 
Background—There is controversy regarding outcome of patients with acute myocarditis (AM), 
and lack of data on how patients admitted with suspected AM are managed. We report 
characteristics, in-hospital management and long-term outcome of patients with AM based on a 
retrospective multi-center registry from 19 Italian hospitals. 
Methods—A total of 684 patients with suspected AM and recent onset of symptoms (<30 days) 
were screened between May 2001 and February 2017. Patients >70 years and those older than 50 
years without coronary angiography were excluded. The final study population comprised 443 
patients (median age 34 years, 19.4% female) with AM diagnosed either by endomyocardial 
biopsy (EMB) or increased troponin plus edema and late gadolinium enhancement at cardiac 
magnetic resonance (CMR).   
Results—At presentation, 118 patients (26.6%) had either left ventricular (LV) ejection fraction 
(EF) <50%, sustained ventricular arrhythmias (VA) or a low cardiac output syndrome (LCOS) 
whilst 325 (73.4%) had no such complications. EMB was performed in 56/443 (12.6%), and a 
baseline CMR was performed in 415/443 (93.7%) of patients. Cardiac mortality plus heart 
transplant (HTx) at 1 and 5 years were 3.0% and 4.1%. Cardiac mortality plus HTx were 11.3% 
and 14.7% in patients with complicated presentation and 0% in uncomplicated cases (Log-rank 
p<0.0001). Major AM-related cardiac events after the acute phase (post-discharge death and 
HTx, sustained VA treated with electrical shock or ablation, symptomatic heart failure needing 
device implantation) occurred in 2.8% at 5-year follow up, with a higher incidence in patients 
with complicated forms (10.8% vs. 0% in uncomplicated AM, Log-rank p<0.0001). Beta 
adrenoceptor blockers were the most frequently employed medications both in complicated 
(61.9%) and in uncomplicated forms (53.8%, p=0.18). After a median time of 196 days, 200 
patients had follow-up CMR and 8/55 (14.5%) with complications at presentation had 
LVEF<50% compared with 1/145 (0.7%) of those with uncomplicated presentation.  
Conclusions—In this contemporary study, overall serious adverse events after AM were lower 
than previously reported. However, patients with LVEF<50%, VA or LCOS at presentation were 
at higher risk compared with uncomplicated cases that had a benign prognosis and low risk of 
subsequent LV systolic dysfunction. 
 
Key Words: Acute myocarditis; outcome; endomyocardial biopsy; cardiac magnetic resonance; 
heart transplantation 
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Clinical Perspective  
 
What is new?  
x Patients with uncomplicated acute myocarditis have benign short and long-term outcome 
although all patients in our series have evidence of increased necrosis biomarkers and late 
gadolinium enhancement at cardiac magnetic resonance. 
x When left ventricular ejection fraction at first cardiac magnetic resonance is preserved, 
the risk of developing an inflammatory cardiomyopathy at mid-term follow up is very 
low.  
x Autoimmune or systemic inflammatory disorders must be investigated in patients with 
acute myocarditis, as an autoimmune disorder can be found in 7.2% of patients admitted, 
and in particular in those with complicated presentation (15.4%). 
 
What are the clinical implications?  
x Patients can be effectively stratified based on their initial clinical presentation: patients 
with left ventricular ejection fraction <50% at first echocardiogram, those with sustained 
ventricular arrhythmias or with low cardiac output syndrome (termed complicated acute 
myocarditis) are at higher risk of cardiac events, compared with those without the above 
manifestations (uncomplicated cases) that are at lower risk. 
x Our overall approach may help identify the most effective allocation of available 
resources, and in particular, does not support the idea that performing an endomyocardial 
biopsy can improve prognosis at least in patients with uncomplicated acute myocarditis. 
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Introduction   
Acute myocarditis (AM) is generally caused by a post-viral immune response, even if other 
triggers have been involved, such as hypersensitivity drug reactions, infections, immune 
checkpoint inhibitors or systemic autoimmune disorders.1-5 Post-mortem examinations in young 
adults have demonstrated that AM was responsible of 3 to 12% of cases of sudden cardiac 
death.6-8 By contrast, in-hospital and long-term outcome of patients admitted with clinically 
suspected AM remains undetermined. So far, most large studies on AM were carried out in 
tertiary referral hospitals, were monocentric and included between 100 and 200 patients,9-12 with 
variable timing of diagnosis from symptom onset.  
 There is evidence that the prognosis of patients with AM can be predicted, at least in part, 
based on the clinical presentation. Patients presenting with ventricular arrhythmias (VA) and/or 
symptoms of heart failure (HF) have worse prognosis compared with those presenting with chest 
pain.11-15 Accordingly, in the United States there is consensus that endomyocardial biopsy 
(EMB) should be performed primarily in those cases with VA and conduction abnormalities, or 
advanced HF of recent onset (i.e. within one month since symptom onset) to exclude 
eosinophilic and giant cell myocarditis (GCM) or cardiac sarcoidosis, that have worse outcome 
and benefit from immune suppression.1, 16, 17 By contrast, European experts recommend 
performing EMB in all clinically suspected AM.18 Nevertheless, in the real-world, the perceived 
usefulness of EBM in the setting of AM is relatively low. Overall, in the United States between 
2002 and 2014, approximately 1 EMB in native heart per million patients has been performed, 
and in 2014 only 8% of these were carried out in clinically suspected AM.19  
 Two recent multicenter studies in over 1,000 patients20, 21 have  proven the incremental 
diagnostic role of cardiac magnetic resonance (CMR) in patients with suspected AM confirming 
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previous studies showing that the presence, location and extent of late gadolinium enhancement 
(LGE) allow detection and quantification of myocardial damage as well as prediction of patient 
outcome. 16, 22, 23,15, 22  
 Finally, although there is preliminary evidence that in young children (1 to 6 years old) 
AM can be followed by dilated cardiomyopathy, it is still debated whether adult patients that 
suffered from AM are at higher risk of developing dilated cardiomyopathy during follow up.1 24  
In this retrospective, multicenter study in 443 patients with AM, we aimed to define the natural 
history of the condition from the time of its diagnosis up to a median follow up of 35 months. 
We studied patients without concurrent cardiac disorder and with symptoms’ onset within one 
month. The diagnosis of AM was confirmed either by EMB or by the combination of positive 
necrosis biomarkers and CMR criteria. Compared with our previous report on patients with AM 
presenting with fulminant vs. nonfulminant forms admitted to 2 referral hospitals, 14 the present 
study is based on a multicenter registry. We enrolled symptomatic patients with a diagnosis of 
AM based either on histology or increased troponin plus edema and LGE at CMR. Here, we 
evaluated beyond cardiac mortality and need for heart transplant (HTx), also major events related 
to AM and in approximately half of cases the changes of volumes and LVEF at CMR. Thus, the 
present study illustrates the clinical characteristics, in-hospital management and long-term 
outcome of a contemporary cohort of patients with AM.    
 
Methods  
The data, analytic methods, and study materials will not be made available to other researchers 
for purposes of reproducing the results or replicating the procedure, as the current approval of the 
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Ethics does not allow to share sensible patients’ data with other researches without local 
Institutional Review Board (IRB) approval. 
Study population and diagnosis of myocarditis 
Patients admitted to 19 hospitals with cath labs and CMR facilities in Lombardy, a northern 
Italian region with a population exceeding 10 million, from May 2001 to February 2017, with 
clinically suspected AM were retrospectively screened and their data centrally revised on pre-
specified criteria for the final inclusion in the dataset.  
 Niguarda hospital in Milan was the coordinating center. The appropriate ethics committee 
(Milano Area C) approved the study (Identifier 120-032016), and the collection of data was 
obtained in accordance with IRB. All the hospitals were at a maximal distance of 100 kilometers 
(62 miles) from the coordinating center with a homogeneous population and similar standards of 
care. The full list of centers is reported in the Supplemental Appendix. 
 Patients were locally identified through the International Classification of Diseases, Ninth 
Revision (ICD9-CM) diagnostic codes (422.0; 422.91; 422.92; 422.93; 422.99; 429.89) recorded 
in hospital discharge forms, or through the hospital lists of cases diagnosed with AM by 
histology or CMR and confirmed by revision of clinical records. The local hospitals were asked 
to consider only those patients with onset of cardiovascular symptoms within 30 days prior to 
admission. Patients with previous or current diagnosis of ischemic heart disease or alternative 
diagnosis at discharge were excluded. Per protocol, only patients with histologically proven 
myocarditis (from EMB, explanted heart or post-mortem examination) or with positive necrosis 
biomarkers (troponins or creatine kinase MB) combined with 2 CMR criteria for AM (edema at 
the dark-blood T2-weighted short tau inversion recovery [STIR] sequence and LGE) and with 
non-ischemic pattern of LGE were included. It has been previously demonstrated that co-
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existence of these 2 “Lake Louise” CMR criteria has a specificity of 91% for the diagnosis of 
AM compared with histology.22 In addition, all patients included in the analysis had no evidence 
of coronary artery disease (patients older than 50 years without available coronary angiography 
were excluded). Furthermore, patients aged over 70 years were excluded as potential 
confounders could not be completely ruled out at CMR (i.e. takotsubo or other conditions 
associated with the ageing heart). Amongst the 684 identified patients, 443 (64.8%) fulfilling the 
pre-specified criteria were included in the final analysis (Figure 1 and Supplemental Table 1). 
Myocardial histology was available in 61 out of 443 (13.7%) patients (EMB in 56 cases, post-
mortem examination in 4 cases and explanted heart in 1 case). Last data on follow up were 
acquired in July 2017. A subset of patients enrolled in the present study (170/443; 38.4%) from 
the Niguarda Hospital in Milan and San Matteo Hospital in Pavia, were also included in our 
previous report.14  
Endpoints 
Main study endpoint was the overall incidence of cardiac death and HTx. Secondary study 
endpoints were: i- all cause deaths and HTx; ii- a composite of major AM-related cardiac events 
that occurred after the acute phase. The latter combined endpoint included cardiac death and 
HTx (excluding in-hospital events), sustained VA treated with electrical shock or ablation, 
symptomatic HF needing device implantation. In the patients with follow-up CMR, prevalence 
of reduced LVEF and evidence of LV dilation (considering the threshold of indexed LV end-
diastolic volume [LVEDV-i] of 105 mL/m2 and 95 mL/m2, for men and women respectively) 
were considered.25   
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Statistical analysis 
Continuous variables are reported as mean±standard deviation (SD) or as median and Q1-Q3, 
according to normal or non-normal distribution as per Shapiro-Wilk normality test. Unpaired 
Student’s t test or Mann-Whitney U test were used as appropriate to compare continuous 
variables. The Wilcoxon matched-paired signed rank test was used to analyze paired data at 
different time points. Categorical variables were compared with Fisher’s exact test and relative-
risk (RR) was calculated. The 95% confidential interval (CI) was calculated with the method of 
Katz.26 Kaplan–Meier (KM) curves were compared with use of the log-rank statistic. All 
analyses were two-tailed. Differences with p values <0.05 were considered statistically 
significant. Software packages used were IBM SPSS Statistics (Version 20) and GraphPad Prism 
(version 6).  
 
Results  
The main characteristics of the study population are reported in Table 1. Median age at 
presentation was 34 years and 19.4% of the patients were females. The most frequent symptom 
at presentation was chest pain (86.6% of patients) followed by dyspnea (19.2%); 80.5% of 
patients had prodromal symptoms.  An associated autoimmune disorder was observed in up to 
7.2% of patients. Eosinophilic granulomatosis with polyangiitis, and mixed connective tissue 
disease were the most frequently observed autoimmune or systemic inflammatory disorders 
(Table 2).  
 The 443 patients were sub-divided into two groups based on the clinical presentation at 
the time of hospital admission. Group 1 (complicated AM) included 118 (26.6%) patients with 
AM complicated by left ventricular systolic dysfunction ( i.e. left ventricular ejection fraction 
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[LVEF] <50%, at first in hospital echocardiogram), documented sustained ventricular 
arrhythmias (VA) or with a fulminant presentation (i.e. low cardiac output syndrome requiring 
inotropes and/or mechanical circulatory support)15, 16 Group 2 (uncomplicated AM) included the 
remaining 325 (73.4%) patients. Follow up was completed in all, but 5 patients (1.1%) that were 
lost after discharge (2 non-European citizens and 3 Italian citizens not resident in Lombardy). 
Median follow up was 35 months (interquartile range [Q1-Q3]: 15-59 months) with a maximum 
follow up of 188 months. The median length of follow up did not differ between the 2 groups 
(p=0.38).  
 According to the pre-specified criteria, complicated AM was present in 118 out of 443 
(26.6%) patients whilst the remaining 325 (73.4%) patients had uncomplicated AM. Females 
were more prevalent in the group with complicated AM. Symptoms of HF were more frequent in 
patients with complicated AM who had lower LVEF at first echocardiogram compared with 
uncomplicated AM.  
 Right ventricular EMB was performed in 56/443 (12.6%) of patients. EMB was 
performed in 47/118 (39.8%) of patients with complicated AM compared with 9/325 (2.8%) of 
those with uncomplicated AM. Histologic evidence of active myocarditis, based on Dallas 
criteria,27 was observed in 50 out of the 56 EMB (89.3%). The most common histological sub-
type was lymphocytic myocarditis both in complicated and uncomplicated AM (67.3% and 
66.7% respectively, Supplemental Table 2).  
 Baseline CMR was performed in 415/443 (93.7%) of the patients and was acquired 
earlier in patients with uncomplicated AM (median delay from hospitalization was 4 days, Q1-
Q3: 3-7 days) compared with those with complicated AM (6 days, Q1-Q3: 3-15 days, p=0.006) 
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(Supplemental Table 2). As per protocol, all 415 patients scanned had evidence of myocardial 
edema and LGE. 
 Treatment differed substantially in the two groups (Supplemental Table 3).  
Immunosuppressive agents, in particular intravenous steroids, were used in up to 37.2% of 
patients presenting with complicated AM compared with 2.8% in those with uncomplicated 
presentation (p<0.0001). Non-steroidal anti-inflammatory drugs were more frequently used in 
patients with uncomplicated presentation than in those with complicated presentation (67.6% vs. 
44%, p<0.0001). Beta adrenoceptor blockers were employed frequently in both groups (61.9% in 
complicated vs. 53.8% in uncomplicated forms, p=0.18) whereas angiotensin converting enzyme 
inhibitors or angiotensin II receptor blockers were used more frequently in patients with 
complicated AM (72.4% vs. 49.1%, p<0.0001). 
Clinical outcome 
In-hospital mortality and HTx in the whole study population (n=443) was 3.2% (10 cardiac 
deaths and 4 HTx) and these events occurred exclusively in patients with complicated AM. 
Furthermore, a venous-arterial extracorporeal membrane oxygenation (VA-ECMO) or a 
ventricular assist device (VAD) was used in 23/443 (5.2%) cases, all with complicated AM.  
Estimated cardiac mortality and HTx at 1, 3 and 5 years of follow up were 3.0%, 3.3% and 4.1%, 
respectively (Figure 2A). As shown in the Figure 2B, cardiac mortality and HTx at 1, 3 and 5 
years of follow up were 11.3%, 12.5% and 14.7% respectively, in the group with complicated 
AM compared with 0% in those with uncomplicated AM (Log-rank p<0.0001). Death from all 
causes and HTx in the whole population at 5 years was 5.2% with a higher incidence in 
complicated vs. uncomplicated cases (18.0% vs. 0.3% respectively, Log-rank p<0.0001, 
Supplemental Figure 1). Major AM-related cardiac events after the acute phase occurred in 
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2.8% at 5-year follow up, with a significantly higher incidence in patients with complicated AM 
(10.8% vs. 0% in uncomplicated AM, Log-rank p<0.0001, Figure 3 and Table 2).  
Changes in left ventricular function at follow up  
Of the 415 patients with a baseline CMR scan, 200 (48.2%) had also a follow up CMR scan after 
a median time of 196 days (Q1-Q3: 126-349 days). The time interval between the two CMR 
scans did not differ between complicated (n = 55) and uncomplicated (n = 145) AM (228 days; 
Q1-Q3: 115-464 days vs. 192 days, Q1-Q3: 132-306 days respectively; p=0.68). In the group 
with complicated AM there was a slight improvement in LVEF at follow up whilst LVEF at 
follow up was unchanged in uncomplicated AM (Figure 4A-B). The proportion of patients with 
reduced LVEF at follow-up CMR was larger in patients with complicated AM compared with 
uncomplicated AM (Figure 4C). At follow up, only 1 out of 145 patients (0.7%) with 
uncomplicated AM had a LVEF below 50% compared with 8 out of 55 (14.5%) of those with 
complicated AM. Similar results were obtained when LVEDV-i was considered (n=190).  A 
larger proportion of patients with complicated AM had LV enlargement at follow up compared 
with those with uncomplicated AM (17.3% vs. 2.9%; RR: 1.17, 95%CI 1.03-1.33, p=0.003) 
(Supplemental Figure 2). 
 
Discussion   
The main finding of the present multicenter study in patients with AM is that cardiac death and 
HTx occurred in 3.2% of patients during hospitalization and in 4.1% of patients at 5-year follow 
up. Although these figures are relatively low compared with previous reports, 9, 12, 15, 28 we 
believe that they are a more realistic reflection of the short and long term outcome of patients 
with AM currently admitted to hospitals. As supporting independent data, a Finnish study on 
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childhood myocarditis also demonstrated relative low occurrence of in-hospital death and HTx 
(1.9%) among all children admitted with AM.29 Differences in patient cohorts and study design 
may explain, at least in part, the discrepancies with previous studies that generally included 
smaller numbers of patients and used non-uniform criteria for diagnosing AM. Some reports 
included only patients with histologically proven AM whilst others enrolled cases of suspected 
AM selected only on the basis of CMR criteria. These differences might have affected the 
estimation of adverse events in the short and long term.30 The inconsistency of currently 
available data is evident if one compares two of the largest studies published so far: one carried 
out in 222 patients where viral AM was diagnosed based on EMB, 15 reported a 15% cardiac 
mortality rate at 5-year follow up; the second study in 205 patients, where AM was surmised on 
the basis of CMR, reported no cardiac deaths at 19 month follow up.31 Two other studies 
published in 2007 and 2008 reported mortality and HTx rates of 14.9% (median follow up 24 
months) and 22% (median follow up 53 months) respectively.11, 12  
 Nevertheless, it must be noted that in the last decade, the diagnosis of AM has been made 
more frequently due to the introduction of sensitive troponins and CMR imaging. This might 
have increased the relative proportion of uncomplicated acute myocarditis in our population, 
resulting in a better outcome compared with older studies, where the diagnosis was mainly based 
on histology. 
 The second relevant result of our study is that, cardiac mortality and HTx both in the 
short (in-hospital, 11.9%) and long term (18.0% at 5 years follow up) occurred exclusively in 
patients with complicated AM, presenting at admission with LVEF below 50% at first 
echocardiogram, sustained VA or hemodynamic instability. Patients with uncomplicated AM had 
more benign short and long-term outcome although all patients had evidence of increased 
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necrosis biomarkers and LGE at CMR. It must be noted that most of the unfavorable events took 
place during the initial hospitalization.  Furthermore, 14.5% of the patients with complicated AM 
had evidence of impaired LV function (i.e. LVEF <50%) at follow up CMR. In line with this, 
evidence of progressive LV dilation at follow up was found in 17.3% of the patients with 
complicated AM compared to only 2.9% of those with uncomplicated AM. In the uncomplicated 
group only one patient with preserved LVEF at baseline CMR had a LVEF below 50% at follow 
up. This patient, despite uncomplicated presentation and LVEF above 55% at baseline CMR, had 
peripheral eosinophilia, that led to perform an EMB demonstrating an eosinophilic myocarditis. 
Peripheral eosinophilia in the scenario of a clinically suspected AM represents a class 2A 
indication for EMB.17, 18 One important message that can be derived from the present study is 
that patients can be effectively stratified based on their initial clinical presentation, main vital 
signs and instrumental findings (ECG and echocardiography)  (Figure 5 and Supplemental 
Figure 3).  
 Another significant difference compared with previous studies is that median LV end 
diastolic diameter was in the normal range (49 mm, including those with complicated AM where 
it was 50 mm) at first echocardiogram, thus confirming a recent onset of the inflammatory 
damage, without evidence of remodeling. The largest monocentric report on myocarditis (n=670) 
published so far bears several important differences compared to our study. The diagnosis of 
myocarditis was based on CMR imaging, 38% of the cases included were outpatients,20 48% of 
the patients had symptoms’ onset above 2 weeks and the median LVEDV was 189 mL (LVEDV-
i above 98 mL/m2). Thus, almost half of the patients had LV dilation at the time of evaluation, 
suggesting an inflammatory damage of longer duration compared with the patients included in 
our study. Furthermore, the median transplant-free survival at 5 years was 95.7%, and main 
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predictors of outcome were age (patients were older compared to our study, i.e. 48 vs. 34 years ), 
presence of LGE (in our study all patients had evidence of LGE, thus it could not be considered 
as potential predictor, but this increased the specificity of the diagnosis of AM in our study) and 
LVEF<40%. It should be noted that in our study the presence of reduced LVEF was a predictor 
of high-risk at follow up.  
 EMB was performed in 12.6% of the patients, primarily in those with complicated AM. 
This is in line with the current indications of the American Heart Association (AHA) and 
American College of Cardiology (ACC).16, 18 Our results demonstrate that the decision not to 
perform an EMB in uncomplicated patients at admission is not associated with an increased risk 
of complications both acutely and in the long term. Our findings do not support the idea that 
performing an EMB can improve prognosis in patients with uncomplicated AM.4  
 On the other hand, our results support the use of CMR both for the diagnosis of AM and 
for patient stratification. Overall, our patients demonstrated relatively small changes in LVEF 
between the baseline CMR, performed during hospitalization or early after discharge, and the 
second CMR scan performed approximately after 200 days from initial admission. It has 
previously been observed that most changes in LVEF in patients with fulminant presentation and 
severe LV dysfunction take place in the first 2 weeks after admission.14 In these patients CMR is 
generally delayed due to hemodynamic instability.14 A transition from AM to dilated 
cardiomyopathy mediated by viral persistence in the myocardium has been suggested in murine 
models.1 The stable/improved LVEDV-i found in most of our patients at follow up does not lend 
support to the hypothesis of progressive LV remodeling late after the acute episode in the 
absence of persistent or recurrent injury.   
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 The present study has pointed out that autoimmune disorders must be investigated, as 
they were found in 7.2% of all AM and in particular in those with complicated presentation 
(15.4%). Therefore, those patients that have systemic autoimmune disorders (such as cardiac 
sarcoidosis or eosinophilic granulomatosis with polyangiitis), must be followed and considered 
at risk of further events and potential evolution to inflammatory cardiomyopathy.1, 16  
 In line with this, there is evidence that pharmacological blocking of multiple immune 
checkpoints by immunotherapy used against cancer (cytotoxic T-lymphocyte-associated antigen 
4 [CTLA-4] by ipilimumab and programmed death-1 [PD-1] by nivolumab) can lead to 
fulminant AM suggesting a key role of immune response in the onset of AM.5 In the setting of 
AM and in particular in patients with complicated presentation, the use of immunosuppressive 
agents such as steroids must be further investigated.  
 Most of the previous studies tested the use of immunosuppressive agents in patients with 
inflammatory cardiomyopathy during the chronic phase.32-35 Also in the Myocarditis Treatment 
Trial (MTT) fewer than 45% of patients were randomized to immunosuppression within 1 month 
since symptoms’ onset.28 Based on our multicenter experience, physicians still use steroids in 
AM (11.4%), especially in patients with complicated AM (37.2% versus 2.8% in uncomplicated 
AM). The current use of immunosuppressive agents is reduced compared with previous series, 
before the MTT trial, where physician used immunosuppressive agents in up to 63% of cases.36  
Nonsteroidal anti-inflammatory drugs (NSAID) were frequently used, without increased risk 
particularly in uncomplicated AM at presentation (in 67.6%). This finding does not support the 
evidence that NSAID worsen the prognosis of viral myocarditis as observed in murine models. 37 
Beta-blockers, that have been suggested to be protective in patients with myocarditis,12 were the 
most frequently used drug in our patients with AM (up to 55.8%), without significant differences 
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between uncomplicated and complicated AM at presentation. Most drugs prescribed in 
uncomplicated AM are not evidence based, in particular the diffuse use of angiotensin converting 
enzyme inhibitors or angiotensin II receptor blockers (in 49.1%). These results remark the need 
for clinical trials to demonstrate the efficacy of these drugs in the setting of AM, in particular in 
those with presence of LGE.20, 21 
 Finally, this registry confirms that AM occurs more frequently in male subjects (about 
80%),38 although women more frequently have complicated AM and are therefore at higher risk 
of complications. The male prevalence observed in our population is consistent with data from 
the nationwide Finnish study (n=213) which included children hospitalized for AM. They 
observed that the prevalence of male sex increased with age, and in children aged 11 to 15 years 
the prevalence of males was 80%.29 Another study focusing on the outcome of patients with 
pericarditis, reported the prevalence of male sex was around 80% in those with myocarditis 
associated with pericarditis (myo-pericarditis or peri-myocarditis) compared with individuals 
with isolated pericarditis where the prevalence of male sex dropped to 54%.39 Similarly, in 2 
other studies on AM diagnosed by CMR with median LVEF above 55%, the prevalence of male 
sex was 77% and 76% respectively.21, 31 The prevalence of male sex can decrease based on the 
inclusion of  high-risk patients, as observed in previous studies where the diagnosis was mainly 
driven by EMB and the mean LVEF was around 40%, with a male prevalence of approximately 
60%.9-11, 40 
Study Limitations  
The retrospective nature of this registry can have introduced potential bias. As the registry spans 
over a 16-year period, the availability of CMR and even EMB could have changed. Nevertheless, 
we believed our population reflects the real-world practice more realistically particularly in 
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regard to the outcome of AM compared with previous monocentric experience of patients with 
EMB. Furthermore, the clinical practice of our 19 hospitals in Lombardy may not be reflected 
elsewhere in Europe or United States particularly regarding the relatively high use of steroids 
and anti-remodeling medications. We cannot exclude that this approach could have impacted on 
the reported more favorable prognosis. Nevertheless, this point stresses again the need for 
randomized clinical trials to assess drugs able to reduce the mortality rate in this particular 
setting of young individuals. Moreover, even if 19 centers participated in this registry, their 
relative contributions were significantly different, as reported in Supplemental Table 1. Finally, 
there was no centralized review of pathology and CMR data in this registry. It must be noted that 
even if there was no core facility for the CMR images the identification of areas with positive 
STIR or LGE, and the calculation of volumes of the LV and LVEF with CMR have high 
accuracy and inter-observer reproducibility.25 The absence of a core echocardiography laboratory 
and the impossibility to retrieve several original echocardiographic images was at the reason why 
we did not report changes in LVEF at follow up based on echocardiography.  
Conclusions 
Our study points out that most cardiac deaths and HTx following AM occur during initial 
hospitalization. We show that integration of clinical data, necrosis biomarkers, CMR and EMB, 
when indicated, can effectively identify patients at increased risk of major adverse events. By 
contrast, we feel that collecting data only from histologically proven AM might lead to 
overestimation of morbidity and mortality. Finally, we provide evidence that when LVEF at first 
CMR is preserved, the risk of developing an inflammatory cardiomyopathy at follow up is very 
low. This overall approach might also help identify the most effective allocation of available 
resources although large multicenter, prospective studies are needed to confirm our findings.  
 by guest on July 4, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.118.035319 
18 
Authors  
Enrico Ammirati, MD, PhD1*; Manlio Cipriani, MD1*; Claudio Moro, MD2;  
Claudia Raineri, MD3; Daniela Pini, MD4; Paola Sormani, MD1; Riccardo Mantovani, MD4; 
Marisa Varrenti, MD1; Patrizia Pedrotti, MD1; Cristina Conca, MD5; Antonio Mafrici, MD5; 
Aurelia Grosu, MD6; Daniele Briguglia, MD7; Silvia Guglielmetto, MD8;  
Giovanni Battista Perego, MD8; Stefania Colombo, MD9; Salvatore Ivan Caico, MD9;  
Cristina Giannattasio, MD, PhD1,10; Alberto Maestroni, MD11; Valentina Carubelli, MD12;  
Marco Metra, MD12; Carlo Lombardi, MD12; Jeness Campodonico, MD13;  
Piergiuseppe Agostoni, MD13,14; Giovanni Peretto, MD15; Laura Scelsi, MD3;  
Annalisa Turco, MD3; Giuseppe Di Tano, MD16; Carlo Campana, MD17;  
Armando Belloni, MD18; Fabrizio Morandi, MD19; Andrea Mortara, MD20; Antonio Cirò, MD21; 
Michele Senni, MD6; Antonello Gavazzi, MD22; Maria Frigerio, MD1; Fabrizio Oliva, MD1†; 
Paolo G. Camici, MD15†; on behalf of the Registro Lombardo delle Miocarditi 
 
Affiliations  
1De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy; 2Desio Hospital, Desio, Italy; 
3Fondazione IRCCS Policlinico San Matteo and the University of Pavia, Pavia, Italy; 4Humanitas 
Clinical and Research Center, Rozzano, Italy; 5San Carlo Borromeo Hospital, Milan, Italy; 6Papa 
Giovanni XXIII Hospital, Bergamo, Italy; 7Mater Domini Humanitas Hospital, Castellanza, 
Italy; 8San Luca Hospital, Istituto Auxologico Italiano, Milan, Italy; 9ASST Valle Olona, 
Gallarate Hospital, Gallarate, Italy; 10University of Milano-Bicocca, Milan, Italy; 11Busto Arsizio 
Hospital, Busto Arsizio, Italy; 12Spedali Civili, University of Brescia, Brescia, Italy; 13Monzino 
Center, IRCCS, Milan, Italy; 14University of Milan, Milan, Italy; 15Vita Salute University and 
 by guest on July 4, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.118.035319 
19 
San Raffaele Hospital, Milan, Italy; 16ASST Cremona, Cremona Hospital, Cremona, Italy; 
17Sant’Anna Hospital, Como, Italy; 18Sacco Hospital, Milan, Italy; 19Ospedale di Circolo e 
Fondazione Macchi, University of Insubria, Varese, Italy; 20Policlinico di Monza, Monza, Italy; 
21San Gerardo Hospital, Monza, Italy; 22FROM Research Foundation Ospedale Papa Giovanni 
XXIII, Bergamo, Italy. 
 
Acknowledgments  
We wish to express our gratitude to Professor Marc Pfeffer, Brigham and Women Hospital 
Boston, United States, for the critical revision of the manuscript. 
 
Sources of Funding  
The Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) section of Lombardy 
promoted the registry contributed to the support of this research. 
 
Disclosures  
None 
 
References 
 
1. Cooper LT, Jr. Myocarditis. N Engl J Med. 2009;360:1526-1538. 
2. Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis--diagnosis, treatment 
options, and current controversies. Nat Rev Cardiol. 2015;12:670-680. 
3. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, Klingel K, Kandolf 
R, Sechtem U, Cooper LT, Bohm M. Update on myocarditis. J Am Coll Cardiol. 
2012;59:779-792. 
4. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio 
T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, 
Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, 
Charron P, Elliott PM, European Society of Cardiology Working Group on M, 
 by guest on July 4, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.118.035319 
20 
Pericardial D. Current state of knowledge on aetiology, diagnosis, management, and 
therapy of myocarditis: A position statement of the european society of cardiology 
working group on myocardial and pericardial diseases. Eur Heart J. 2013;34:2636-2648, 
2648a-2648d. 
5. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, 
Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-
Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, 
Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube 
JM, Diaz LA, Jr., Anders RA, Sosman JA, Moslehi JJ. Fulminant myocarditis with 
combination immune checkpoint blockade. N Engl J Med. 2016;375:1749-1755. 
6. Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently 
normal heart. Cardiovasc Res. 2001;50:399-408. 
7. Harmon KG, Drezner JA, Maleszewski JJ, Lopez-Anderson M, Owens D, Prutkin JM, 
Asif IM, Klossner D, Ackerman MJ. Pathogeneses of sudden cardiac death in national 
collegiate athletic association athletes. Circ Arrhythm Electrophysiol. 2014;7:198-204. 
8. Maron BJ, Haas TS, Ahluwalia A, Murphy CJ, Garberich RF. Demographics and 
epidemiology of sudden deaths in young competitive athletes: From the united states 
national registry. Am J Cardiol.. 2016;129:1170-1177. 
9. McCarthy RE, 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, 
Baughman KL. Long-term outcome of fulminant myocarditis as compared with acute 
(nonfulminant) myocarditis. N Engl J Med. 2000;342:690-695. 
10. Magnani JW, Danik HJ, Dec GW, Jr., DiSalvo TG. Survival in biopsy-proven 
myocarditis: A long-term retrospective analysis of the histopathologic, clinical, and 
hemodynamic predictors. Am Heart J. 2006;151:463-470. 
11. Caforio AL, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, Ramondo A, Carturan 
E, Iliceto S, Thiene G, Daliento L. A prospective study of biopsy-proven myocarditis: 
Prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 
2007;28:1326-1333. 
12. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger 
A, Bohm M. Predictors of outcome in patients with suspected myocarditis. Circulation. 
2008;118:639-648 
13. Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, Salvi A, 
Perkan A, Di Lenarda A, Bussani R, Bartunek J, Sinagra G. Long-term evolution and 
prognostic stratification of biopsy-proven active myocarditis. Circulation. 
2013;128:2384-2394. 
14. Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, Petrella D, 
Garascia A, Pedrotti P, Roghi A, Bonacina E, Moreo A, Bottiroli M, Gagliardone MP, 
Mondino M, Ghio S, Totaro R, Turazza FM, Russo CF, Oliva F, Camici PG, Frigerio M. 
Survival and left ventricular function changes in fulminant versus nonfulminant acute 
myocarditis. Circulation. 2017;136:529-545. 
15. Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, 
Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H. Long-term follow-up of biopsy-
proven viral myocarditis: Predictors of mortality and incomplete recovery. J Am Coll 
Cardiol. 2012;59:1604-1615. 
16. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, Francis GS, Lenihan 
D, Lewis EF, McNamara DM, Pahl E, Vasan RS, Ramasubbu K, Rasmusson K, Towbin 
 by guest on July 4, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.118.035319 
21 
JA, Yancy C, American Heart Association Committee on Heart F, Transplantation of the 
Council on Clinical C, Council on Cardiovascular Disease in the Y, Council on C, Stroke 
N, Council on E, Prevention, Council on Quality of C, Outcomes R. Current diagnostic 
and treatment strategies for specific dilated cardiomyopathies: A scientific statement 
from the american heart association. Circulation. 2016;134:e579-e646. 
17. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati F. Eosinophilic 
myocarditis: Characteristics, treatment and outcomes. J Am Coll Cardiol. 2017;70:2363-
2375. 
18. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, 
Narula J, Starling RC, Towbin J, Virmani R, American Heart A, American College of C, 
European Society of C, Heart Failure Society of A, Heart Failure Association of the 
European Society of C. The role of endomyocardial biopsy in the management of 
cardiovascular disease: A scientific statement from the american heart association, the 
american college of cardiology, and the european society of cardiology. Endorsed by the 
heart failure society of america and the heart failure association of the european society 
of cardiology. J Am Coll Cardiol. 2007;50:1914-1931. 
19. Singh V, Mendirichaga R, Savani GT, Rodriguez A, Blumer V, Elmariah S, Inglessis-
Azuaje I, Palacios I. Comparison of utilization trends, indications, and complications of 
endomyocardial biopsy in native versus donor hearts (from the nationwide inpatient 
sample 2002 to 2014). Am J Cardiol. 2018;121:356-363. 
20. Grani C, Eichhorn C, Biere L, Murthy VL, Agarwal V, Kaneko K, Cuddy S, Aghayev A, 
Steigner M, Blankstein R, Jerosch-Herold M, Kwong RY. Prognostic value of cardiac 
magnetic resonance tissue characterization in risk stratifying patients with suspected 
myocarditis. J Am Coll Cardiol. 2017;70:1964-1976. 
21. Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, Pepe A, 
Todiere G, Lanzillo C, Scatteia A, Di Roma M, Pontone G, Perazzolo Marra M, Barison 
A, Di Bella G, Cardiac Magnetic Resonance Working Group of the Italian Society of C. 
Cardiac mr with late gadolinium enhancement in acute myocarditis with preserved 
systolic function: Itamy study. J Am Coll Cardiol. 2017;70:1977-1987. 
22. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White 
JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, 
Kumar A, Pauschinger M, Liu P, International Consensus Group on Cardiovascular 
Magnetic Resonance in M. Cardiovascular magnetic resonance in myocarditis: A jacc 
white paper. J Am Coll Cardiol. 2009;53:1475-1487. 
23. Baccouche H, Mahrholdt H, Meinhardt G, Merher R, Voehringer M, Hill S, Klingel K, 
Kandolf R, Sechtem U, Yilmaz A. Diagnostic synergy of non-invasive cardiovascular 
magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients 
without coronary artery disease. Eur Heart J 2009;30:2869-2879. 
24. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, 
Lurie PR, Hsu D, Canter C, Wilkinson JD, Lipshultz SE. Incidence, causes, and 
outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867-1876. 
25. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, Turkbey 
EB, Williams R, Plein S, Tee M, Eng J, Bluemke DA. Normal values for cardiovascular 
magnetic resonance in adults and children. J Cardiovasc Magn Reson. 2015;17:29. 
26. Katz D, Baptista J, Azen SP, Pike MC. Obtaining confidence intervals for the risk ratio in 
cohort studies. Biometrics. 1978;34:469-474. 
 by guest on July 4, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.118.035319 
22 
27. Aretz HT. Myocarditis: The dallas criteria. Human pathology. 1987;18:619-624. 
28. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, 
Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. The 
myocarditis treatment trial investigators. N Engl J Med. 1995;333:269-275. 
29. Arola A, Pikkarainen E, Sipila JO, Pykari J, Rautava P, Kyto V. Occurrence and features 
of childhood myocarditis: A nationwide study in finland. J Am Heart Assoc.  
2017;6:e005306. 
30. Cooper LT, Jr. When lightning strikes: Fulminant myocarditis in the realm of 
inflammatory cardiomyopathies. Circulation. 2017;136:546-548. 
31. Sanguineti F, Garot P, Mana M, O'H-Ici D, Hovasse T, Unterseeh T, Louvard Y, 
Troussier X, Morice MC, Garot J. Cardiovascular magnetic resonance predictors of 
clinical outcome in patients with suspected acute myocarditis. J Cardiovasc Magn Reson. 
2015;17:78. 
32. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of 
immunosuppressive therapy in patients with virus-negative inflammatory 
cardiomyopathy: The timic study. Eur Heart J. 2009;30:1995-2002. 
33. Parrillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenner M, Schaer GL, 
Palmeri ST, Cannon RO, 3rd, Alling D, Wittes JT, Ferrans VJ, Rodriguez ER, Fauci AS. 
A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N 
Engl J Med. 1989;321:1061-1068. 
34. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, 
Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM. Controlled trial of 
intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 
2001;103:2254-2259. 
35. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, 
Niklewski T, Zembala M, Polonski L, Rozek MM, Wodniecki J. Randomized, placebo-
controlled study for immunosuppressive treatment of inflammatory dilated 
cardiomyopathy: Two-year follow-up results. Circulation. 2001;104:39-45. 
36. Davidoff R, Palacios I, Southern J, Fallon JT, Newell J, Dec GW. Giant cell versus 
lymphocytic myocarditis. A comparison of their clinical features and long-term 
outcomes. Circulation. 1991;83:953-961. 
37. Costanzo-Nordin MR, Reap EA, O'Connell JB, Robinson JA, Scanlon PJ. A nonsteroid 
anti-inflammatory drug exacerbates coxsackie b3 murine myocarditis. J Am Coll Cardiol. 
1985;6:1078-1082. 
38. Fairweather D, Cooper LT, Jr., Blauwet LA. Sex and gender differences in myocarditis 
and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38:7-46. 
39. Imazio M, Brucato A, Barbieri A, Ferroni F, Maestroni S, Ligabue G, Chinaglia A, 
Cumetti D, Della Casa G, Bonomi F, Mantovani F, Di Corato P, Lugli R, Faletti R, 
Leuzzi S, Bonamini R, Modena MG, Belli R. Good prognosis for pericarditis with and 
without myocardial involvement: Results from a multicenter, prospective cohort study. 
Circulation. 2013;128:42-49. 
40. Grogan M, Redfield MM, Bailey KR, Reeder GS, Gersh BJ, Edwards WD, Rodeheffer 
RJ. Long-term outcome of patients with biopsy-proved myocarditis: Comparison with 
idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995;26:80-84. 
 
  
 by guest on July 4, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.118.035319 
23 
Table 1. Clinical presentation and initial diagnostic findings in 443 patients admitted with clinically suspected 
acute myocarditis (AM) 
 
 No. of patients 
with available 
data 
Acute myocarditis p 
All Complicated 
presentation 
Uncomplicated 
presentation 
No.  443 118 325  
Age–yr median(Q1-Q3) 443 34(24-42) 35(22-45) 33(24-42) 0.46 
Age <15 yrs-no.(%)  14(3.2) 7(5.9) 7(2.2) 0.06 
Female-no.(%) 443 86(19.4) 37(31.4) 49(15.1) 0.0002 
Caucasian ethnicity –no.(%) 443 407(92.1) 104(88.1) 303(93.2) 0.11 
Clinical presentation-no.(%)      
Dyspnea 437 84(19.2) 64(55.7) 20(6.2) <0.0001 
Chest pain 437 379(86.7) 68(59.1) 311(96.6) <0.0001 
Syncope 437 27(6.2) 19(16.5) 8(2.5) <0.0001 
Fulminant presentation* 443 38(8.6) 38(32.2) 0(0) <0.0001 
Fever-no.(%) 437 282(64.5) 73(63.5) 209(64.9) 0.82 
Prodromal  Symptoms-no.(%) 437 352(80.5) 94(81.7) 258(80.1) 0.78 
Sore throat-no.(%) 437 161(36.8) 44(38.3) 117(36.3) 0.74 
Respiratory tract infection-no.(%) 437 10(2.3) 6(5.2) 4(1.2) 0.02 
Gastrointestinal disorders-no.(%) 437 126(28.8) 36(31.3) 90(28.0) 0.55 
Patients with Associated Auto-immune 
disorders†-no.(%) 430 31(7.2) 18(15.4) 13(4.2) 0.0002 
Previous myocarditis-no.(%) 443 5(1.1) 2(1.7) 3(0.9) 0.61 
ECG at admission-no.(%) 426     
Normal  61(14.3) 8(7.6) 53(16.5) 
<0.0001 ST segment elevation  245(57.5) 45(42.9) 200(62.3) Other abnormal ST-T segment  100(23.5) 39(37.1) 61(19.0) 
Bundle branch block  20(4.7) 13(12.4) 7(2.2) 
Any AV block no.(%) 427 13 10(9.6) 3(0.9) <0.0001 
Laboratory findings       
Increased CRP at admission-no.(%) 414 333(80.4) 89(84.0) 244(79.2) 0.32 
Increased troponin -T/-I/CK-MB at admission-no.(%) 437 434(99.3) 111(99.1) 323(99.4) 1 
Echocardiography at admission-no.(%) 431 431(97.3) 112(94.9) 319(98.2) 0.09 
LVEF-%(Q1-Q3) 428 55(50-60) 35(20-45) 60(55-60) <0.0001 
LVEDD-mm median (Q1-Q3)(only patients ≥15yrs) 246 49(46-52) 50(46-55) 48(46-50) 0.050 
RV-TAPSE<18 mm or evidence of visual 
dysfunction no.(%) 
259 22(8.5) 19(30.6) 3(1.5) <0.0001 
Presence of pericardial effusion-no.(%) 397 102(25.7) 41(38.7) 61(21.0) 0.0007 
Coronary angiography or CT angiography 
performed-no.(%) 
434 203(46.8) 57(50.0) 146(45.6) 0.45 
No evidence of CAD -no.(%) 203 203(100) 57(100) 146(100) - 
* Fulminant presentation indicates patients with low cardiac output syndrome requiring inotropes and/or mechanical circulatory support. 
† See Table S1 in the Supplementary Appendix for details regarding associated autoimmune disorders. 
Yrs indicates years; Q1-Q3, first and third quartile; AV, atrio-ventricular; CRP, C-reactive protein; CK-MB, creatine kinase isoenzyme 
MB; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; RV-TAPSE, right ventricular tricuspid 
annular plate systolic excursion; CT, computed tomography; CAD, coronary artery disease.  
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Table 2. Associated autoimmune or systemic inflammatory disorders in patients with clinically suspected acute 
myocarditis (available data 430 out of 443; 97.1%) 
 
 All AM AM with other 
Autoimmune/ 
inflammatory 
disorders 
Complicated 
AM with other 
Autoimmune/ 
inflammatory 
disorders 
Uncomplicated 
AM with other 
Autoimmune/ 
inflammatory 
disorders 
p 
Patients with Associated autoimmune/ 
inflammatory disorders-no./total  31/430 18/117 13/313 - 
Patients with Multiple autoimmune/ 
inflammatory disorders-no.(%) 2/430(0.5) 2/31(6.5) 1(5.5) 1(7.7) - 
EGPA-no.(%) 6/430(1.4) 6/31(19.4) 6(33.0) 0(0) - 
Mixed connective tissue disease-no.(%) 5/430(1.2) 5/31(16.1) 3(16.7) 2(15.4) - 
Autoimmune hypothyroidism –no.(%) 4/430(0.9) 4/31(12.9) 2(11.1) 2(15.4) - 
Inflammatory bowel disease-no.(%) 4/430(0.9) 4/31(12.9) 1(5.5) 3(23.1) - 
Sarcoidosis -no.(%) 3/430(0.7) 3/31(9.7) 2(11.1) 1(7.7) - 
Isolated Asthma-no.(%) 3/430(0.7) 3/31(9.7) 1(5.5) 2(15.4) - 
      
Autoimmune hyperthyroidism-no.(%) 2/430(0.5) 2/31(6.5) 1(5.5) 1(7.7) - 
SLE-no.(%) 1/430(0.2) 1/31(3.2) 1(5.5) 0(0) - 
Antiphospholipid syndrome- no.(%) 1/430(0.2) 1/31(3.2) 1(5.5) 0(0) - 
Psoriasis- no.(%) 1/430(0.2) 1/31(3.2) 0(0) 1(7.7) - 
Celiac disease no.(%) 1/430(0.2) 1/31(3.2) 0(0) 1(7.7) - 
Autoimmune hepatitis no.(%) 1/430(0.2) 1/31(3.2) 1(5.5) 0(0) - 
Multiple sclerosis-no.(%) 1/430(0.2) 1/31(3.2) 1(5.5) 0(0) - 
GVHD-no.(%) 1/430(0.2) 1/31(3.2) 0(0) 1(7.7) - 
Unknown-no.(%) 1/430(0.2) 1/31(3.2) 1(5.5) 0(0) - 
AM indicates acute myocarditis; EGPA, Eosinophilic granulomatosis with polyangiitis; SLE, systemic lupus erythematosus; 
GVHD, graft-versus-host-disease 
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Table 3. Events that occurred in 443 patients admitted with clinically suspected acute 
myocarditis (AM) 
 
 Acute myocarditis p 
All Complicated  
at presentation 
Uncomplicated  
at presentation 
No. 443 118 325  
In-hospital events:     
Overall deaths no.(%) 10(2.3) 10(8.5) 0(0) <0.0001 
Cardiac deaths-no.(%) 10(2.3) 10(8.5) 0(0) <0.0001 
Non-cardiac deaths-no.(%) 0(0) 0(0) 0(0) - 
HTx-no.(%) 4(0.9) 4(3.4) 0(0) 0.005 
VAD-no.(%) 5(1.1) 5(4.2) 0(0) 0.001 
Va-ECMO-no.(%) 18(4.1) 18(15.3) 0(0) <0.0001 
Lost after discharge no.(%) 5(1.1) 2(0.8) 3(0.9)  
     
Post-discharge events:     
No. 428 106 322  
Overall deaths –no.(%) 7(1.6) 6(5.7) 1(0.3) 0.001 
Cardiac deaths-no.(%) 2*(0.5) 2*(1.9) 0(0) - 
Non-cardiac deaths-no.(%) 5(1.2) 4(3.8)† 1(0.3)† - 
HTx-no.(%) 2(0.5) 2(1.9) 0(0) - 
SVT treated with shock/ablation-no.(%) 4(0.9) 4(3.8) 0(0) 0.004 
CRT implant-no.(%) 1(0.2) 1(0.8) 0(0) - 
     
Other events:     
ICD implant-no.(%) 9(2.0) 8(6.8) 1(0.3)‡ <0.0001 
Recurrence of AM-no.(%) 11(2.6) 1(0.9) 10(3.1) 0.31 
STEMI -no.(%) 2(0.5) 0(0) 2(0.6) - 
* On patient died after heart transplantation due to severe graft rejections and graft dysfunction (initial 
diagnosis: giant cell myocarditis).  
† Non cardiac deaths were caused by suicide in 2 patients, cancer in 1 and infection in another one in the 
complicated AM group and by cancer in 1 patient in the uncomplicated AM group.  
‡ The patient was initially admitted for a syncope and diagnosed with a suspected AM.  In the follow up 
an ambulatory ECG monitoring demonstrated a non-sustained asymptomatic ventricular arrhythmia, thus 
he was implanted. No ventricular arrhythmias were further recorded after ICD implantation. 
HTx, heart transplantation; VAD, ventricular assist device; va-ECMO, venoarterial extracorporeal 
membrane oxygenation; SVT, sustain ventricular tachycardia; CRT cardiac resynchronization therapy; 
ICD, implantable cardiac defibrillator; AM, acute myocarditis, STEMI, ST-elevation myocardial 
infarction. 
 
  
 by guest on July 4, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.118.035319 
26 
Figure Legends 
 
Figure 1. Flow diagram illustrating screening and inclusion criteria. 
  
Figure 2. Kaplan-Meier estimates of 5 years cardiac mortality and heart transplantation  
A, events in the whole study population with AM and B, events in patients with AM complicated 
at presentation by left ventricular ejection fraction <50%, sustained ventricular arrhythmias or a 
low cardiac output syndrome compared with patients without such complications at presentation. 
Of total cardiac deaths and heart transplantation, 16 patients initially presented with fulminant 
presentation and 1 with ventricular arrhythmias. One cardiac death occurred after heart 
transplantation and was omitted. 
 
Figure 3. Kaplan-Meier estimates of 5 years composite of major acute myocarditis-related 
cardiac events after the acute episode. A, events in the overall patient with AM and B, events 
in patients with AM complicated at presentation by left ventricular ejection fraction <50%, 
sustained ventricular arrhythmias or a low cardiac output syndrome compared AM patients 
uncomplicated at presentation. The composite of major acute myocarditis -related cardiac events 
that occurred after the acute phase included cardiac death and heart transplantation (excluding in-
hospital events), sustained ventricular arrhythmias treated with electrical shock or ablation, 
symptomatic heart failure needing device implantation.   Three patients who died in the follow 
up had initially a fulminant presentation, 2 patients who were transplanted in the follow up had 
initially a fulminant presentation, 2 patients who had a sustained ventricular arrhythmias treated 
with shock or ablation in the follow up had initially a sustained ventricular arrhythmias and 2 
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patients had a fulminant presentation, 1  patient who was implanted with a cardiac 
resynchronization therapy device due to symptomatic heart failure in the follow up had initially a 
left ventricular ejection fraction below 50%.  
Figure 4. Changes in left ventricular ejection fraction (LVEF) between baseline and follow-
up (median time of 196 days) cardiac magnetic resonance. A, Patients with complicated 
myocarditis at presentation had a significant improvement of left ventricular systolic function, B, 
patients with uncomplicated myocarditis had a similar LVEF at follow up (Wilcoxon matched-
pair signed-rank test was used for comparisons). C, the proportion of patients with a LVEF 
below 55%, considering a threshold for impaired left ventricular systolic function at CMR was 
higher among patients with complicated myocarditis. Categorical variables were compared with 
Fisher’s exact test and relative-risk (RR) was calculated. CI indicates confidential interval. 
Figure 5. Risk stratification of patients with acute myocarditis (AM) based on initial 
clinical presentation, main vital signs and instrumental findings.  
Based on the results of the registry, complicated AM based on left ventricular ejection fraction 
(LVEF) <50% at first echocardiogram (ECHO), presence of ventricular arrhythmias (VA) at 
ECG or evidence of hemodynamic instability (low cardiac output syndrome [LCOS] at hospital 
admission can effectively identify patients at risk of death, heart transplantat (HTx) and long-
term ventricular assist device (LT-VAD) during hospitalization (increased-risk AM group). 
Further information of reduced LVEF (<55%) at baseline cardiac magnetic resonance (CMR) 
associated with the initial clinical presentation can effectively identify those patients at risk of 
further major AM-related cardiac events (composite of cardiac death, HTx, sustained VA treated 
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with electrical shock or ablation and symptomatic heart failure needing device implantation) in 
the follow up or those at risk of having a reduced LVEF at a follow-up CMR. In particular, the 
prognosis in term of events and risk of LVEF impairment is minimal in patients with 
uncomplicated AM at presentation and LVEF equal or above 55% at baseline CMR (low-risk 
AM group). The proportion of AM-related events were significantly higher in the high-risk 
group compare with low risk group (9.5% vs. 0; p=0.0008, Fisher’s exact test was used). 
Similarly, proportion of patients with LVEF<55% at follow up was significantly high in the high 
risk-group compared with low-risk group: 21.6% vs. 3.9% (relative risk for LVEF<55% at 
follow up 5.49 [95%confidence interval] 2.10-14.4; p=0.0002). BP indicated blood pressure. 
*The number of patients included in the follow up after discharge was the sum of those with a 
baseline and a follow-up CMR (N=200) plus one patient (with complicated presentation) who 
had a baseline CMR and had an event in the follow up who prevented him/her to undergo the 
follow-up CMR.  
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 1 
CLINICAL PRESENTATION AND OUTCOME IN A CONTEMPORARY COHORT OF PATIENTS WITH 
ACUTE MYOCARDITIS: THE MULTICENTER LOMBARDY REGISTRY  
Ammirati and Cipriani et al. On behalf of the Registro Lombardo delle Miocarditi Outcome of 
acute myocarditis 
 
 
SUPPLEMENTAL MATERIALS 
 
SUPPLEMENTAL METHODS 
List of participating centers: 
In Milano: Niguarda Hospital, coordinating center; San Carlo Hospital; Humanitas Hospital; San Luca 
Auxologico Hospital; Monzino Hospital; Sacco Hospital; San Raffaele Hospital. In Monza: Policlinico 
Hospital; Desio Hospital; San Gerardo Hospital. In Varese: Mater Domini Humanitas Hospital; Gallarate 
Hospital; Fondazione Macchi Hospital; Busto Arsizio Hospital. In Brescia: Civili Hospital. In Cremona: H 
Spitali. In Pavia: San Matteo Hospital. In Bergamo: Papa Giovanni XXIII Hospital. In Como: Sant’Anna 
Hospital. All hospitals are in Italy.
 2 
Supplemental TABLE 1. Causes of exclusion of patients with clinically suspected myocarditis in each hospital 
In bold are reported the name of the provinces/towns where the hospitals are located. CMR indicates cardiac magnetic resonance; N, number; H, hospital. 
 3 
 
	 	 Age≥70yrs		
	
Age	51-69yrs	
without	
coronary	
angiography		
NO	
CMR	
No	CMR	
criteria	
No	
troponin	
increase	
Unavailable	
troponin	
Others		 Excluded	
(%	total)	
Total	 Included	
Milano	 	 	 	 	 	 	 	 	 	 	
H	Niguarda	 4	 -	 10	 6	 4	 1	 1	 26(17.1)	 152	 126	
H	San	Carlo	 4	 -	 7	 2	 -	 -	 -	 13(36.8)	 38	 25	
H	Humanitas	 3	 2	 -	 6	 -	 -	 4	 15(26.3)	 57	 42	
H	Auxologico	 2	 -	 6	 -	 -	 -	 -	 8(30.8)	 26	 18	
H	Monzino	 3	 -	 23	 2	 1	 -	 1	 30(73.2)	 41	 11	
H	Sacco	 -	 -	 1	 1	 1	 -	 -	 3(33.3)	 9	 6	
H	San	Raffaele	 -	 -	 -	 -	 12	 -	 1	 13(38.2)	 34	 21	
	 	 	 	 	 	 	 	 	 	 	
Monza	 	 	 	 	 	 	 	 	 	 	
H	Policlinico	 1	 -	 3	 4	 -	 -	 -	 8(100)	 8	 0	
H	Desio	 -	 3	 -	 -	 -	 -	 -	 3(4.8)	 62	 59	
H	San	Gerardo	 -	 -	 1	 -	 1	 -	 -	 2(40.0)	 5	 3	
	 	 	 	 	 	 	 	 	 	 	
Varese	 	 	 	 	 	 	 	 	 	 	
H	Mater	Domini	 -	 1	 -	 1	 5	 -	 -	 7(41.2)	 17	 10	
H	Gallarate	 -	 -	 -	 3	 -	 -	 -	 3(20.0)	 15	 12	
H	Macchi	 -	 -	 33	 2	 1	 -	 2	 38(90.5)	 42	 4	
H	Busto	 -	 1	 -	 -	 -	 -	 -	 1(8.3)	 12	 11	
	 	 	 	 	 	 	 	 	 	 	
Brescia	 	 	 	 	 	 	 	 	 	 	
H	Civili	 3	 2	 2	 3	 2	 -	 -	 12(50.0)	 24	 12	
	 	 	 	 	 	 	 	 	 	 	
Cremona	 	 	 	 	 	 	 	 	 	 	
H	Spitali	 3	 -	 20	 3	 -	 -	 -	 26(86.7)	 30	 4	
	 	 	 	 	 	 	 	 	 	 	
Pavia	 	 	 	 	 	 	 	 	 	 	
 4 
 	
H	San	Matteo	 -	 1	 7	 1	 -	 -	 -	 9(15.5)	 58	 49	
	 	 	 	 	 	 	 	 	 	 	
Bergamo	 	 	 	 	 	 	 	 	 	 	
H	Papa	Giovanni	
XXIII	
-	 -	 3	 12	 -	 -	 -	 15(36.6)	 41	 26	
	 	 	 	 	 	 	 	 	 	 	
Como	 	 	 	 	 	 	 	 	 	 	
H	Sant’Anna	 -	 3	 -	 6	 	 	 	 9(69.2)	 13	 4	
	 	 	 	 	 	 	 	 	 	 	
N	of	HOSPITALS	
(n=19)	
	 	 	 	 	 	 	 241(35.2)	 684	 443	
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Supplemental TABLE 2. Pathology and cardiac magnetic resonance findings in 443 patients with 
clinically suspected acute myocarditis (AM) 
                Complicated AM  
 
             Uncomplicated 
              AM  
P 
HISTOLOGY  VALUE  VALUE  
 
EMB performed 
no.(%) 
 47/118 
(39.8) 
  9/325 
(2.8) 
<0.0001 
Active myocarditis  
no.(%) 
 43/47(91.5)  7/9(77.8) 0.24 
Borderline/negative 
for myocarditis  
no.(%) 
 4*/47(8.5)  2/9(22.2) 
      
Post-transplant 
examination 
without EMB no.(%) 
 1/118(0.8)  0 - 
Post-mortem 
examination 
without EMB no.(%) 
 4/118(3.3)  0 - 
Overall available 
histology no.(%) 
 52/118 
(44.1) 
 9/325 
(2.8) 
<0.0001 
Specific forms of 
myocarditis 
     
Lymphocytic 
myocarditis  no.(%) 
 35/52(67.3)  6/9(66.7) 1 
Giant cell 
myocarditis  no.(%) 
 7/52(13.4)  0 - 
Cardiac sarcoidosis  
no.(%) 
 2/52(3.8)  0 - 
Eosinophilic 
myocarditis  no.(%) 
 6/52(11.5)  1/9(11.1) 1 
Borderline/Negative  
no.(%) 
 2/52(3.8)  2/9(22.2) 0.10 
      
CMR pts with 
available 
data 
VALUE pts with 
available 
data 
  
CMR performed-
no.(%) 
118 90(76.3) 325 325(100) <0.0001 
Time to CMR since 
admission-days(Q1-
Q3) 
81 6(3-15) 302 4(3-7) 0.006 
LVEF-%(Q1-Q3) 81 54(43-60) 304 61(56-66) <0.0001 
LVEDV-indexed-
mL/m2 (Q1-Q3) 
78 80 
(70-98) 
299 80 
(72-90) 
0.42 
      
 
 6 
CMR indicates cardiac magnetic resonance; EMB, endomyocardial biopsy; LVEDV, left ventricular 
end-diastolic volume; LVEF, left ventricular ejection fraction; Q1–Q3, first–third quartiles; and 
STIR, T2-weighted short tau inversion recovery. 
*Three patients had negative endomyocardial biopsy but positive histology at post mortem 
analysis, and another patient had negative endomyocardial biopsy but positive histology on 
explanted heart. 
 
 
 
Supplemental TABLE 3. Immunosuppressive regimens and heart failure medications in in 443 
patients with clinically suspected acute myocarditis 
 
 Complicated AM  
 
Uncomplicated AM P 
 No. of patients 
with available 
data 
VALUE 
No. of patients 
with available 
data 
VALUE 
 
Immunosuppressive 
therapy-  n(%) 113 42(37.2) 324 8(2.8) <0.0001 
I.v. steroids-  n(%) 94     30(31.9) 231 2(0.9) <0.0001 
Only oral steroids-  
n(%) 94 10(10.6) 231 5(2.2) 0.002 
IVIG-  n(%) 86 7(8.1) 229 0(0) <0.0001 
 Cyclosporine-  n(%) 75 6(8.0) 160 1(0.6) 0.005 
 Azathioprine-  n(%) 74 3(4.1) 159 2(1.3) 0.33 
Other 
Immunosuppressive 
drug-  n(%) 
74 7(9.5) 90 1(1.1) 0.02 
NSAID-  n(%) 109 48(44.0) 324 219(67.6) <0.0001 
      
ACEi/ARBs-  n(%) 105 76(72.4) 324 159(49.1) <0.0001 
Beta-blockers-  n(%) 105 65(61.9) 325 175(53.8) 0.18 
MRAs-  n(%) 105 25(23.8) 320 10(3.1) <0.0001 
Amiodarone-  n(%) 100 7(7.0) 322 0(0) <0.0001 
Ivabraidine-  n(%) 101 8(7.9) 319 3(0.9) 0.0008 
 
I.v., intravenous; I.v.Ig, intravenous immunoglobulins; cyA; NSAID, Nonsteroidal anti-inflammatory drug; 
ACEi, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; MRAs, 
mineralocorticoid receptor antagonist. 
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Supplemental Figure 1. Kaplan-Meier estimates of 9 years overall mortality and heart transplantation  
A, events in the overall patient with AM and B, events in patients with AM complicated at presentation by left ventricular ejection fraction <50%, 
sustained ventricular arrhythmias or a low cardiac output syndrome compared AM patients uncomplicated at presentation. 
 
 
0 365 730 1095 1460 1825 2190 2555 2920 3285
0
5
10
15
20
25
30
LVSD/VA/F	at	presentation
Uncomplicated	presentation
11.3%
0.3%
15.9%
0.3% 0.3% 0.3%
No.	at	risk
Log-rank	(Mantel-Cox)	p<0.0001
18.0%
27.1%
0.3%
Acute	myocarditis	N=443
1											2											3										4										5											6											7											8										9
Follow	up	(years)
15.9%
325								275									219												160										119											75													51												30												18												13
118										84												66														57												47												31													23												15												12													8
O
ve
ra
ll	
de
at
h	
an
d	
HT
x	
(%
)
0 365 730 1095 1460 1825 2190 2555 2920 3285
0
5
10
15
20
25
30
ALL	AM
3.2% 4.4% 4.4%
8.8%
No.	at	risk
5.2%
Acute	myocarditis	N=443
1											2											3										4										5											6											7											8										9
Follow	up	(years)
443									356											282										214										164									105												74												45												30													21
5.2%
O
ve
ra
ll	
de
at
h	
an
d	
HT
x	
(%
)
A) B)
FIGURE	S1
Complicated presentation
 8 
 
Baseline Follow up
0
20
40
60
80
100
120
140
160
180
MALE PATIENTS
Changes at CMR
p=0.38
(N=41)
Myocarditis complicated by
             LVSD/VA/F
82 mL/m2
  (74-93)
79 mL/m2
  (68-94)
LV
ED
V-
i (
m
L/
m
2 )
B)A)
Baseline Follow up
0
20
40
60
80
100
120
140
160
180 FEMALE PATIENTS
Changes at CMR
p=0.78
(N=20)
 72±11
mL/m2
Uncomplicated myocarditis
73±9
mL/m2
LV
ED
V-
i (
m
L/
m
2 )
Baseline Follow up
0
20
40
60
80
100
120
140
160
180 FEMALE PATIENTS
Changes at CMR
p=0.56
(N=11)
Myocarditis complicated by
             LVSD/VA/F
77±22
 mL/m2
81±27
 mL/m2
LV
ED
V-
i (
m
L/
m
2 )
D)C)
>105	mL/m2
>95	mL/m2
>95	mL/m2
>105	mL/m2
Baseline Follow up
0
20
40
60
80
100
120
140
160
180 MALE PATIENTS
Changes at CMR
p=0.005
(N=118)
 83 mL/m2
(74-92)
Uncomplicated myocarditis
 79 mL/m2
(73-88)
LV
ED
V-
i (
m
L/
m
2 )
1 2
0
25
50
75
100
125
150
Normal LV
Enlarged LV
LVSD/VA/F Uncomplicated
All Acute myocarditis
CMR at follow up
  9/52
(17.3%)
 4/138
 (2.9%)
Risk of LV
dilation
after »200 days
RR=1.17
(95%CI
1.03-1.33)
p=0.003
N
 o
f p
at
ie
nt
s
E)
at presentation at presentation
ONLINE	FIGURE	2
Complicated myocarditis
at presentation
Complicated myocarditis
at presentation
Complicated Uncomplicated
myocarditis
 9 
Supplemental Figure 2. Changes in indexed left ventricular end-diastolic volume (LVEDV-i) comparing the baseline cardiac magnetic resonance 
(CMR) with the follow-up CMR at a median time of 196 days in 190 patients with available data.  
A, Male and B, female patients with complicated myocarditis at presentation had a similar LVEDV-I at follow up. C, LVEDV-I changes in male and 
D, female patients between baseline and follow-up CMR. E, the proportion of patients with a dilated left ventricle, considering a threshold in men 
of 105 mL/m2 and in female of 95 mL/m2 at CMR was higher among patients with complicated myocarditis. Categorical variables were compared 
with Fisher’s exact test and relative-risk (RR) was calculated. CI indicates confidential interval. 
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Supplemental Figure 3. Exemplificative clinical cases of patients with acute myocarditis (AM) at increased-risk presenting with complicated AM 
and low-risk with uncomplicated AM.   
(A-C) Case 1: (A) In 2008, a 46-year-old man from Sri Lanka, with a previous normal chest X ray performed for screening (2007) and without 
cardiac disorders presented at emergency department with heart failure (HF) symptoms. (B) Chest X ray at admission showed signs of pulmonary 
congestion. First echocardiogram reported left ventricular ejection fraction (LVEF) of 47%. Troponin T was 4.5 ug/L (x150-fold the upper limit [0.03 
µg/L]) and CK-MB 56 µg/L. Suddenly he developed low output cardiac syndrome (LCOS) and needed for inotropes. Coronary angiogram was 
normal; thus, the patient was diagnosed with a clinically suspected complicated acute myocarditis. During hospitalization, he had ventricular 
fibrillation (VF) and died. (C) Autopsy revealed diffuse lymphocytic myocarditis. (D-F) Case 2: In 2015, a 16-year-old man was admitted due to 
chest pain. (D) First echocardiogram showed severe systolic dysfunction (LVEF of 20%, Supplemental Video 1) with stable hemodynamic (high 
sensitivity [hs] troponin T was 2293 ng/L [x164-fold the upper limit of 14 ng/L]) with CKMB of 11 µg/L. The diagnosis of complicated acute 
myocarditis was formulated.  (E) Endomyocardial biopsy (EMB) showed lymphocytic myocarditis. Systolic function recovered after administration 
of intravenous pulsed corticosteroid therapy and at discharge he had a complete recovery at echocardiogram (LVEF 57%, Supplemental Video 2). 
No cardiac magnetic resonance (CMR) was performed at discharge.  (F) At follow-up, the patient was asymptomatic without events for 2 years, 
and CMR after 5 months (2 chamber view with evidence of mid-wall late gadolinium enhancement in the anterior and inferior walls) confirmed 
functional recovery (LVEF 68%, Supplemental Video 3) but with mild dilation of the left ventricle (LV: indexed LV end-diastolic volume [LVEDV-i] of 
128 mL/m2, considering in male a cut-off for dilation beyond 105 ml/m2) despite initiation of ramipril, bisoprolol and spironolactone during 
hospitalization. (G-I) Case 3: In 2016, a 35-year-old man was admitted with chest pain and dyspnoea. (G) First echocardiogram showed LVEF of 
29% (Supplemental Video 4, echo-color-Doppler apical 4 chamber view) and hs troponin T was 3195 ng/L (x228 fold the upper limit) and CKMB 
102 µg/L thus the patient was admitted with a diagnosis of clinically suspected complicated AM. The same day, due to low cardiac output 
syndrome, inotropes and intra-aortic balloon pump (IABP) were initiated. (H) EMB showed an eosinophilic myocarditis that was treated with 
intravenous pulsed corticosteroid therapy with significant recovery of the systolic function weaning off IABP at day 4 and inotropes at day 12. 
After 18 days, the day before discharge (hs troponin 119 ng/L (x8 fold the upper limit) and CKMB 1.8 µg/L (the upper limit was 5 µg/L), he 
experienced a cardiac arrest due VF that was successfully treated, and the (I) CMR performed the same day showed a LVEF of 41% (Supplemental 
Video 5).  In the follow up, the patient remained asymptomatic with no further events and no arrhythmias recorded by the defibrillator that was 
implanted after in-hospital VF. CMR after approximately 4 months showed LVEF of 40% (Supplemental Video 6, 2-chamber view, artefacts are 
due the presence of the device) and dilated LV (LVEDV-i of 136 mL/m2). 
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(J-L) Case 4: In 2017, a 19-year-old man presented with chest pain. First hs troponin T was 1688 ng/L (x121-fold the upper limit) and CKMB 11 µg/L 
with LVEF was above 60%. The patient was admitted with a diagnosis of uncomplicated acute myocarditis. During hospitalization, a CMR was 
performed with normal LV volumes (LV-EDV-i 81 ml/m2) and systolic function (LVEF 62%, Supplemental Video 7) with positive LGE (J) and signs of 
oedema at T2-weighted short tau inversion recovery (STIR, K) involving the anterior, lateral and infero-lateral walls. (L) At follow up the patient 
was asymptomatic without events and CMR showed no more oedema and normal systolic function (LVEF 60%, Supplemental Video 8) and 
volumes LV-EDV-i 68 ml/m2).   
 
SUPPLEMENTAL VIDEO LEGENDS 1-8  
Please refer to the Supplemental figure legend 3. 
 
APPENDIX 
Additional investigators from the Registro Lombardo delle Miocarditi:  
Martina Briani, MD; Humanitas Clinical and Research Center in Rozzano, Milan; Italy 
Tania Odello, MD; Ospedale di Circolo e Fondazione Macchi, University of Insubria in Varese; Italy 
Paolo Botti, MD; Sant’Anna Hospital in Como; Italy 
Erika Bertelli, MD; ASST Cremona, Cremona Hospital in Cremona; Italy 
Claudio Apruzzese, MD; Sacco Hospital in Milan; Italy 
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Tiziana Spezzano, MD; and Monica Wu, MD, both in Fondazione IRCCS Policlinico San Matteo and the University of Pavia, in Pavia; Italy 
